Rice Hall James & Associates LLC Increases Holdings in Evolus, Inc. $EOLS

Rice Hall James & Associates LLC boosted its position in Evolus, Inc. (NASDAQ:EOLS) by 17.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,168,886 shares of the company’s stock after purchasing an additional 172,846 shares during the period. Rice Hall James & Associates LLC’s holdings in Evolus were worth $7,177,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of EOLS. Frazier Life Sciences Management L.P. acquired a new stake in Evolus in the second quarter valued at $22,431,000. Soleus Capital Management L.P. grew its stake in Evolus by 96.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock valued at $19,516,000 after acquiring an additional 1,039,842 shares during the last quarter. Pinnacle Associates Ltd. purchased a new position in Evolus during the 2nd quarter valued at about $6,318,000. First Light Asset Management LLC purchased a new position in Evolus during the 2nd quarter valued at about $4,795,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in Evolus during the first quarter worth about $5,851,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Trading Up 0.7%

Shares of NASDAQ:EOLS opened at $6.90 on Friday. The firm has a market cap of $447.26 million, a price-to-earnings ratio of -7.50 and a beta of 0.87. The stock’s 50-day moving average price is $6.91 and its two-hundred day moving average price is $7.55. Evolus, Inc. has a 12-month low of $5.71 and a 12-month high of $17.12.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05. Evolus had a negative net margin of 20.49% and a negative return on equity of 759.04%. The business had revenue of $68.97 million for the quarter, compared to analyst estimates of $91.23 million. As a group, research analysts forecast that Evolus, Inc. will post -0.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research note on Monday. Needham & Company LLC restated a “hold” rating on shares of Evolus in a research report on Wednesday. Wall Street Zen upgraded Evolus from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Mizuho reduced their target price on shares of Evolus from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Monday, December 1st. Finally, BTIG Research reiterated a “buy” rating and set a $18.00 price target on shares of Evolus in a report on Monday, September 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Evolus presently has an average rating of “Moderate Buy” and an average price target of $20.80.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.